Patents by Inventor Maria Melina Soares

Maria Melina Soares has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20250011794
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: June 18, 2024
    Publication date: January 9, 2025
    Inventors: Nagaraj GOVINDAPPA, Kedarnath SASTRY, Maria Melina SOARES
  • Anti-EGFR1-PD1 targeted/immunomodulatory fusion protein
    Patent number: 12049632
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: July 30, 2024
    Assignee: Biocon Limited
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20210301296
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: June 4, 2021
    Publication date: September 30, 2021
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
  • CTLA4/PD1 targeted/immunomodulatory fusion proteins
    Patent number: 11028399
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: June 8, 2021
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20200399379
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Inventors: NAGARAJ GOVINDAPPA, MARIA MELINA SOARES, KEDERNATH SASTRY
  • Fusion immunomodulatory proteins and methods for making same
    Patent number: 10766963
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: September 8, 2020
    Inventors: Nagaraj Govindappa, Maria Melina Soares, Kedernath Sastry
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20190367929
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 5, 2019
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
  • Epidermal growth factor receptor targeted/immunomodulatory fusion proteins and methods of use for them
    Patent number: 10385348
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: August 20, 2019
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • Targeted/TGF-ßRII fusion proteins and methods for making same
    Patent number: 10144934
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: December 4, 2018
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20180251560
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Application
    Filed: May 1, 2018
    Publication date: September 6, 2018
    Inventors: NAGARAJ GOVINDAPPA, MARIA MELINA SOARES, KEDERNATH SASTRY
  • Fusion immunomodulatory proteins and methods for making same
    Patent number: 9988456
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: June 5, 2018
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Maria Melina Soares, Kedernath Sastry
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20180066057
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: October 27, 2017
    Publication date: March 8, 2018
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • Method of treating cancer with an EGFR targeted immunomodulatory fusion protein
    Patent number: 9809651
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: November 7, 2017
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • Anti-CTLA4 antibody-TGF-?RII targeted/immunomodulatory fusion proteins
    Patent number: 9758582
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: September 12, 2017
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20170233747
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 17, 2017
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20160237155
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: May 3, 2016
    Publication date: August 18, 2016
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20160168260
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 16, 2016
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
  • Targeted/immunomodulatory fusion proteins and methods for making same
    Patent number: 9340617
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: May 17, 2016
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20160009807
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 14, 2016
    Inventors: NAGARAJ GOVINDAPPA, MARIA MELINA SOARES, KEDERNATH SASTRY
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20140356362
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: August 13, 2014
    Publication date: December 4, 2014
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES